

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Global burden of spondyloarthritis in low-and-middle income countries: a systematic review and meta-analysis protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041180
Article Type:	Protocol
Date Submitted by the Author:	02-Jun-2020
Complete List of Authors:	<p>ALLADO, Edem; Nancy Regional University Hospital Center, University Center of Sports Medicine and Adapted Physical Activity ; Lorraine European University Centre, EA 3450 DevAH, Development, Adaptation and Disadvantage. Cardiorespiratory regulations and motor control, MOUSSU, Anthony; Nancy Regional University Hospital Center, University Center of Sports Medicine and Adapted Physical Activity Bigna, Jean Joel; Centre Pasteur of Cameroon, Department of Epidemiology and Public Health HAMROUN, Sabrina; Paris University CAMIER, Aurore; INSERM, UMR1153 Center for Research in Epidemiology and StatisticS (CRESS), Research Team on Early Life Origins of Health (EAROH) CHENUÉL, Bruno; Nancy Regional University Hospital Center, 1. University Center of Sports Medicine and Adapted Physical Activity ; Lorraine European University Centre, EA 3450 DevAH, Development, Adaptation and Disadvantage. Cardiorespiratory regulations and motor control, HAMROUN, Aghiles ; Paris-Saclay University, Centre for Research in Epidemiology and Population Health; Lille University Hospital Center, Nephrology Dialysis and Kidney Transplantation Department</p>
Keywords:	RHEUMATOLOGY, EPIDEMIOLOGY, IMMUNOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Global burden of spondyloarthritis in low-and-middle income countries: a systematic review and**
4
5 2 **meta-analysis protocol**
6
7

8 3 Edem Allado^{1,2,3}, Anthony Moussu¹, Jean Joel Bigna⁴, Sabrina Hamroun⁵, Aurore Camier⁶, Bruno
9 4 Chenuel^{1,2}, Aghilès Hamroun^{7,8}
10
11
12

13 5 **Author affiliations**
14
15

- 16 6 1. Center of Sports Medicine and Adapted Physical Activity - Regional University Hospital Center
17 of Nancy, F-54000, Nancy, France.
18
19 7 2. Development, Adaptation and Disadvantage. Cardiorespiratory regulations and motor
20 8 2. Development, Adaptation and Disadvantage. Cardiorespiratory regulations and motor
21 8 2. Development, Adaptation and Disadvantage. Cardiorespiratory regulations and motor
22 9 control (EA 3450 DevAH), University of Lorraine, F-54505, France
23 9 control (EA 3450 DevAH), University of Lorraine, F-54505, France
24 10 3. Department rheumatology - Regional University Hospital Center of Nancy, F-54000, Nancy,
25 10 3. Department rheumatology - Regional University Hospital Center of Nancy, F-54000, Nancy,
26 11 France
27 11 France
28 12 4. Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé,
29 12 4. Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé,
30 13 Cameroon
31 13 Cameroon
32 14 5. Université de Paris, F-75006, Paris, France
33 14 5. Université de Paris, F-75006, Paris, France
34 15 6. INSERM, UMR1153 Center for Research in Epidemiology and Statistics (CRESS), Research
35 15 6. INSERM, UMR1153 Center for Research in Epidemiology and Statistics (CRESS), Research
36 16 Team on Early Life Origins of Health (EAROH), 75004 Paris, France
37 16 Team on Early Life Origins of Health (EAROH), 75004 Paris, France
38 17 7. Centre for Research in Epidemiology and Population Health, Paris-Saclay University, UMRS
39 17 7. Centre for Research in Epidemiology and Population Health, Paris-Saclay University, UMRS
40 18 1018, Villejuif, France
41 18 1018, Villejuif, France
42 19 8. University of Lille, Regional University Hospital Centre of Lille, Nephrology Dialysis and Kidney
43 19 8. University of Lille, Regional University Hospital Centre of Lille, Nephrology Dialysis and Kidney
44 20 Transplantation Department, F-59000 Lille, France
45 20 Transplantation Department, F-59000 Lille, France
46 21
47 21
48 21
49 21

50 21 **Corresponding author:**
51

52 22 Edem ALLADO, MD, MSc
53

54 23 Center of Sports Medicine and Adapted Physical Activity, Regional University Hospital Center of Nancy,
55 23 Center of Sports Medicine and Adapted Physical Activity, Regional University Hospital Center of Nancy,
56 24 F-54000, Nancy, France
57 24 F-54000, Nancy, France
58

59 25 Mail : e.allado@chru-nancy.fr
60

26 **Abstract**

27 **Introduction**

28 In recent years, the definition of spondyloarthritis (SpA) has seen major modifications with respect of
29 diagnostic tools and classification. With the advent of biotherapies, treatment possibilities in patients
30 with SpA have substantially improved in the last few years, the effect being all the more beneficial
31 when the diagnosis is made at an early course of the disease. This is then of great interest to obtain
32 accurate data on the disease prevalence, especially in the regions where data remain scarce such as
33 low-and-middle income countries (LMICs), in order to measure and understand the needs of health
34 care systems. Therefore, through a global systematic review and meta-analysis, the current study aims
35 at investigating the prevalence of SpA and Human Leukocyte Antigen B27 (HLAB27), and its association
36 with the risk of SpA in the global population of LMICs.

37 **Methods and analysis**

38 We will include cohort, case-control and cross-sectional studies performed among adults (> 15 years)
39 living in LMICs. EMBASE, Medline, Global Index Medicus, and Web of Knowledge will be searched for
40 relevant records published until 30 September 2019, without any language restriction. The review will
41 be reported according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE)
42 guidelines. After screening of titles and abstracts, study selection, data extraction and risk of bias
43 assessment by two independent reviewers, we shall assess the studies individually for clinical and
44 statistical heterogeneity. Random-effect meta-analysis will be used to pool studies judged to be
45 clinically homogenous. The Egger's test and visual inspection of funnel plots will be used to assess
46 publication bias. Results will be presented by World Health Organization (WHO) sub-regions.

47 **Ethics and dissemination**

48 Since primary data are not collected in this study, ethical approval is not required. This review is
49 expected to provide relevant data on the epidemiology of SpA, HLAB27 and their association in the
50 global population of LMICs. The final report will be published in a peer-reviewed journal.

1
2
3 51 **Prospero registration number** CRD42020163898
4
5

6 52 **Strengths and limitations of this study**
7

- 8
9 53 - This will be the first systematic review summarizing data on the global burden of SpA in LMICs,
10
11 54 and its association with HLAB27.
12
13 55 - Rigorous methods and robust statistical analyses will be used to minimize bias and provide
14
15 56 accurate data.
16
17 57 - No language restriction will be applied, hence, allowing to include a maximum number of
18
19 58 studies in this review.
20
21 59 - Limited number of studies on the topic may represent an important shortcoming, especially
22
23 60 for data regarding HLAB27 status.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

73 Introduction

74 Spondyloarthritis (SpA) is a common disease that affects 0.5 to 2% of the global population¹⁻³. This
75 pathology is characterized by chronic inflammatory pain and debilitating stiffness, manifesting most
76 often in young adult men⁴⁻⁶. It is associated with a negative impact on mental health, quality of life
77 and professional activity, generating significant costs^{1,4,7,8}. The delay to diagnose this pathology is
78 often long, up to 10 years after the symptoms' onset, thus increasing the disease burden^{9,10}. In our
79 modern era of new targeted therapies, it became essential to reduce this diagnostic delay, these
80 treatments being all the more effective as the disease is taken care at an early-stage^{11,12}.

81 The concept and definition of SpA have evolved significantly over the past thirty years¹³⁻¹⁵, leading to
82 the current Assessment of Spondyloarthritis International Society (ASAS) classification criteria, and
83 distinguishing two main forms of the disease according to its clinical and radiological phenotype:
84 radiographic and non-radiographic forms^{16,17}. The ASAS classification criteria also gives a central place
85 to the detection of the Human Leukocyte Antigen B27 (HLAB27) in the diagnostic and early referral
86 process¹⁸. SpA prevalence data seem to highlight a strong association with the frequency of HLAB27
87^{19,20}, although this association is not homogeneous depending on the areas of the globe: in fact, we
88 note a frequent co-occurrence in Western countries (around 90%), which would drop to 50% in the
89 Arab countries and become virtually zero in sub-Saharan Africa where the prevalence of the HLAB27
90 antigen is very low (less than 1%)²¹⁻²³. Nevertheless, these global estimates are not generalizable to
91 the population of low-and-middle income countries (LMICs), where the data are based on scattered
92 studies, with small patient numbers, and in a limited sample of countries (LMICs)²⁴. It is thus difficult
93 to distinguish the exact cause of the data heterogeneity, whether linked to demographic or genetic
94 characteristics of the population, frequent under-diagnosis due to a lack of suitable health care
95 facilities and rheumatologists, or methodological biases in data reporting²⁴.

96 Accordingly, we propose this global systematic review and meta-analysis protocol to critically
97 synthesize current evidence on the burden of SpA in LMICs population. This study will provide

1
2
3 98 evidence-based and useful data that may raise awareness in healthcare providers, researchers and
4
5 99 policy makers for improved detection and management of SpA in the global population of LMICs.
6
7

8 100 **Review question**

9
10
11 101 What is the epidemiology of spondyloarthritis (and its axial form) and HLAB27 in low-and-middle-
12
13 102 income countries?
14
15

16 103 **Objectives**

17
18
19 104 This systematic review and meta-analysis aims at:

- 20
21
22 105 1. Determining the prevalence of axial spondyloarthritis in the global population (asymptomatic
23
24 106 or referring for inflammatory back pain) of LMICs
25
26 107 2. Determining the prevalence of HLAB27 in the global population (asymptomatic, symptomatic
27
28 108 and diagnosed spondyloarthritis) of LMICs
29
30 109 3. Determining the association between HLAB27 and the risk of spondyloarthritis in LMICs
31
32
33

34 110 **Methods and analysis**

35
36
37 111 This systematic review and meta-analysis will be reported in conformity with the Meta-analysis Of
38
39 112 Observational Studies in Epidemiology (MOOSE) guidelines ²⁵. The Preferred Reporting Items for
40
41 113 Systematic Review and Meta-Analysis Protocol (PRISMA-P) was used to report this protocol ²⁶. The
42
43 114 PRISMA-P checklist is attached as online **supplementary file 1**.
44
45

46 115 **Criteria for considering studies for the review**

47
48
49 116 Spondylarthritis (SpA) will be diagnosed on the basis of clinical and imaging features, in accordance
50
51 117 with 'Assessment of SpondyloArthritis international Society' (ASAS), 'European Spondyloarthropathy
52
53 118 Study Group' (ESSG), New York, Rome or Amor criterion ^{13,14,18,27}. The presence of sacroiliitis will be
54
55 119 assessed by MRI, CT-scan or X-ray, according to the modified New York criteria. HLAB27 detection will
56
57 120 be assessed by ELISA, flow cytometry assay, genetic sequence-based, or micro-lymphocytotoxicity
58
59
60

1
2
3 121 methods ^{28,29}. Study where a different definition of SpA would have been used will be retrieved as well
4
5 122 and a subgroup analysis will be conducted to assess the effect of the definition on the overall summary
6
7 123 effect.
8
9

10 124 **Specific criteria for estimating the prevalence of spondyloarthritis and HLAB27 in the global**
11
12
13 125 **population of LMICs**

- 14
15 126 1. Population: we will include studies with adults (> 15 years) whether they are asymptomatic,
16
17 127 symptomatic (i.e. inflammatory back pain, for example) or have a diagnosed spondyloarthritis.
18
19 128 2. Outcomes: we will consider studies reporting the prevalence of spondyloarthritis and/or
20
21 129 HLAB27, or studies having enough data to compute these estimates; which are number of SpA
22
23 130 or HLAB27 cases and total sample size.
24
25 131 3. Study design: we will consider cross-sectional and cohort studies.
26
27
28
29

30 132 **Specific criteria for investigating the association between HLAB27 and risk for SpA**

- 31
32 133 1. Population: we will consider adults (> 15 years) with or without any specific condition or
33
34 134 disease.
35
36 135 2. Exposure will be defined as being HLAB27 positive.
37
38 136 3. Comparator will be defined as a confirmed absence of HLAB27 detection. Patients with
39
40 137 'Confirmed absence of HLAB27 detection' are HLAB27 negative using the same method of
41
42 138 diagnostic as those HLAB27 positive.
43
44 139 4. Outcome will be the presence of SpA, including its axial form, according to prespecified
45
46 140 diagnostic criteria.
47
48 141 5. We will consider cross-sectional, case-control and cohort studies. We will consider studies in
49
50 142 which both patients HLAB27 positive (exposed group) and HLAB27 negative (non-exposed
51
52 143 group) will be included; and where the proportion of patients with SpA was reported in both
53
54 144 groups.
55
56
57
58
59

60 145 **Search strategy for identifying relevant studies**

1
2
3 146 The search strategy will be conducted as follows.
4
5

6 147 **Bibliographic database searches**

7
8

9 148 Relevant records will be identified by searching EMBASE, PubMed, Global Index Medicus and Web of
10
11 149 knowledge from inception to 30 September 2019. Text words and medical subject heading terms
12
13 150 related to SpA and HLAB27 will be used including: 'ankylosing spondylitis', 'sacroiliitis', 'Bechterew
14
15 151 Disease', 'Spondyloarthritis Ankylopoietica', 'Marie Struempell Disease', 'spine disease', and 'HLA-
16
17 152 B27'. The name of the LMICs (as defined by the World Bank Classification ³⁰) in the language relevant
18
19 153 to each country will also be applied. **Supplementary file 2** shows the full search strategy for EMBASE
20
21 154 that will be adapted to fit with other databases. No language restriction will be applied. For articles
22
23 155 published in a language other than English and French, an experienced translator in the concerned
24
25 156 language will be contacted for translation.
26
27
28
29

30 157 **Searching for other sources**

31
32

33 158 We will scan the references of all relevant articles for additional relevant data sources missed during
34
35 159 our search, and their full-texts will be retrieved. References of pertinent reviews will also be scanned.
36
37

38 160 **Selection of studies for inclusion in the review**

39
40

41 161 All references identified after implementation of the search strategy will be imported inside the Zotero
42
43 162 software. All records obtained from various databases will be combined in a single Zotero library, and
44
45 163 the duplicates will be removed. Two reviewers (AH and EA) will independently evaluate the studies
46
47 164 obtained from the searches, using an assessment form to ensure that the selection criteria are reliably
48
49 165 applied. These reviewers will screen the titles and abstracts of papers obtained, after which the full
50
51 166 texts of potentially eligible papers will be retrieved by one reviewer (AH). The two reviewers will
52
53 167 independently review the full text of each potentially eligible study, compare their results and resolve
54
55 168 any discrepancy by discussion. For duplicates, studies published in more than one report, the one
56
57
58
59
60

169 reporting the largest sample size will be considered. Studies with inaccessible full text either online or
170 from the corresponding author will be excluded.

171 **Assessment of methodological quality and reporting of data**

172 Methodological quality and risk of bias of included studies will be independently assessed by two
173 reviewers using the Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) tool for
174 studies investigating the association between HLAB27 and SpA³¹. For studies investigating prevalence
175 estimates, we will use the risk of bias tool developed by Hoy and colleagues³².

176 **Data extraction and management**

177 A data extraction form will be used to collect information on the surname of the first author, year of
178 publication, country where the study was conducted, study design, study area (rural, urban), sampling
179 method, timing of data collection, population setting (general population, hospitalized patients), type
180 of population (healthy asymptomatic, inflammatory back pain, SpA diagnosed patients), method of
181 SpA diagnostic, method of HLAB27 detection, mean or median age, proportion of males, specific
182 characteristics of the study population, sample size, number of cases of SpA, and number of HLAB27
183 positive cases. For multinational studies, the data will be reported for the individual countries. Where
184 it will be impossible to disaggregate data for such studies by country, the available data will be
185 presented as a single study, and the individual countries which participated in the study will be
186 reported. We will exclude studies in which relevant data are impossible to extract even after contacting
187 the corresponding author.

188 **Data synthesis and analysis**

189 For measuring the association between HLAB27 positivity and risk of SpA, a meta-analysis using the
190 random-effects method of DerSimonian and Laird will be performed to pool weighted Odds Ratios
191 (ORs) of risk estimates³³. ORs will be reported with their 95% confidence intervals (CIs), and 95%
192 prediction intervals³⁴.

1
2
3 193 For prevalence synthesis, unadjusted prevalences with their respective standard errors will be
4
5 194 recalculated based on the information of crude numerators and denominators provided by individual
6
7 195 studies. The variance of the study-specific prevalence will be stabilized with the Freeman-Tukey double
8
9 196 arc-sine transformation, before pooling the data using a random-effects meta-analysis model ³⁵. All
10
11 197 pooled estimate will be reported with 95% CI and 95% prediction interval. Heterogeneity will be
12
13 198 assessed using the χ^2 test on Cochran's Q statistic, and quantified by calculating I² ³⁶. Values of 25%,
14
15 199 50% and 75% for I², will respectively represent low, medium and high heterogeneity. We will assess
16
17 200 the presence of publication bias using funnel plots inspection (if ≥ 10 studies) and the Egger's test (if \geq
18
19 201 3 studies) ³⁷. When there will be enough data, meta-regression and subgroup analyses will be
20
21 202 performed to investigate the possible sources of heterogeneity using the aforementioned variables
22
23 203 and the study methodological quality. We plan to do subgroup analysis according to: SpA form (all
24
25 204 forms confounded or axial form), population type, population settings, WHO subregions, and the
26
27 205 definition used to diagnose SpA. In case of substantial clinical heterogeneity, a narrative summary of
28
29 206 findings will be done. The inter-rater agreement for study inclusion between investigators will be
30
31 207 assessed using Cohen's κ coefficient ³⁸. Data analyses will be done using the 'meta' package of the
32
33 208 statistical software R v.3.6.2.

209 **Presentation and reporting of results**

41
42 210 The study selection process will be summarized using a flow diagram. Quantitative data will be
43
44 211 presented in tables of individual studies, and in summary tables, or forest plots where appropriate.
45
46 212 The quality score of bias for each eligible study will be reported accordingly.

213 **Patient and public involvement**

51
52 214 Patients and the public were not involved in the design or planning of the study.

215 **Potential amendments**

1
2
3 216 We do not plan to modify the protocol to avoid reporting bias. However, if necessary, any amendment
4
5 217 in the review process will be reported for transparency.
6
7

8 218 **Ethics and dissemination**

9
10
11 219 Since primary data are not collected in this study, ethical approval is not required. This review is
12
13 220 expected to provide accurate data on SpA and HLAB27 prevalences, as well as an estimation of their
14
15 221 association in LMICs. The final report will be published in a peer-reviewed journal.
16
17

18 222 **Review status**

19
20
21 223 Preliminary searches.
22
23

24 224 **References**

- 25
26
27 225 1. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. *J Rheumatol Suppl.* 2006
28 226 Sep;78:4–11.
- 29
30 227 2. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence
31 228 of ankylosing spondylitis. *Rheumatology (Oxford).* 2014 Apr 1;53(4):650–7.
- 32
33 229 3. Dougados M, Baeten D. Spondyloarthritis. *Lancet.* 2011 Jun 18;377(9783):2127–37.
- 34
35 230 4. Poddubnyy D, Rudwaleit M. Early spondyloarthritis. *Rheum Dis Clin North Am.* 2012
36 231 May;38(2):387–403.
- 37
38 232 5. Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. *Nat Rev Dis Primers.* 2015
39 233 09;1:15013.
- 40
41 234 6. Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. *Best
42 235 Practice & Research Clinical Rheumatology.* 2006 Jun 1;20(3):401–17.
- 43
44 236 7. Martindale J, Shukla R, Goodacre J. The impact of ankylosing spondylitis/axial spondyloarthritis
45 237 on work productivity. *Best Pract Res Clin Rheumatol.* 2015 Jun;29(3):512–23.
- 46
47 238 8. Zhao S, Thong D, Miller N, Duffield SJ, Hughes DM, Chadwick L, et al. The prevalence of
48 239 depression in axial spondyloarthritis and its association with disease activity: a systematic
49 240 review and meta-analysis. *Arthritis Res Ther.* 2018 11;20(1):140.
- 50
51 241 9. Zhao S, Pittam B, Harrison NL, Nursiah K, Goodson NJ, Hughes DM. Systematic review and
52 242 meta-analysis of diagnostic delay in axial spondyloarthritis. 2020 Apr 8 [cited 2020 May 24];
53 243 Available from: <http://livrepository.liverpool.ac.uk/3081611>
- 54
55 244 10. Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, Economic, and Humanistic Burden
56 245 Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review. *Rheumatol
57 246 Ther.* 2020 Mar;7(1):65–87.

- 1
2
3 247 11. Sykes MP, Doll H, Sengupta R, Gaffney K. Delay to diagnosis in axial spondyloarthritis: are we
4 248 improving in the UK? *Rheumatology (Oxford)*. 2015 Dec;54(12):2283–4.
- 6 249 12. Seo MR, Baek HL, Yoon HH, Ryu HJ, Choi H-J, Baek HJ, et al. Delayed diagnosis is linked to worse
7 250 outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. *Clin*
8 251 *Rheumatol*. 2015 Aug;34(8):1397–405.
- 10 252 13. Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. *Rev*
11 253 *Rhum Mal Osteoartic*. 1990 Feb;57(2):85–9.
- 14 254 14. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European
15 255 Spondylarthropathy Study Group preliminary criteria for the classification of
16 256 spondylarthropathy. *Arthritis Rheum*. 1991 Oct;34(10):1218–27.
- 18 257 15. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing
19 258 spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum*. 1984
20 259 Apr;27(4):361–8.
- 22 260 16. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development
23 261 of Assessment of SpondyloArthritis international Society classification criteria for axial
24 262 spondyloarthritis (part I): classification of paper patients by expert opinion including
25 263 uncertainty appraisal. *Ann Rheum Dis*. 2009 Jun;68(6):770–6.
- 28 264 17. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development
29 265 of Assessment of SpondyloArthritis international Society classification criteria for axial
30 266 spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*. 2009 Jun;68(6):777–
31 267 83.
- 33 268 18. Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. *Nat Rev*
34 269 *Rheumatol*. 2012 Apr 10;8(5):262–8.
- 36 270 19. Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA-B27 in the US:
37 271 data from the US National Health and Nutrition Examination Survey, 2009. *Arthritis Rheum*.
38 272 2012 May;64(5):1407–11.
- 40 273 20. Khan MA. HLA-B27 and its subtypes in world populations. *Curr Opin Rheumatol*. 1995
41 274 Jul;7(4):263–9.
- 44 275 21. Mustafa KN, Hammoudeh M, Khan MA. HLA-B27 Prevalence in Arab Populations and Among
45 276 Patients with Ankylosing Spondylitis. *J Rheumatol*. 2012 Aug;39(8):1675–7.
- 47 277 22. Ziade NR. HLA B27 antigen in Middle Eastern and Arab countries: systematic review of the
48 278 strength of association with axial spondyloarthritis and methodological gaps. *BMC*
49 279 *Musculoskelet Disord*. 2017 Jun 29;18(1):280.
- 51 280 23. Mathieu A, Paladini F, Vacca A, Cauli A, Fiorillo MT, Sorrentino R. The interplay between the
52 281 geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune
53 282 diseases: a unifying hypothesis. *Autoimmun Rev*. 2009 Mar;8(5):420–5.
- 56 283 24. Stolwijk C, Onna M van, Boonen A, Tubergen A van. Global Prevalence of Spondyloarthritis: A
57 284 Systematic Review and Meta-Regression Analysis. *Arthritis Care & Research*. 2016;68(9):1320–
58 285 31.
- 60

- 1
2
3 286 25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of
4 287 observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational
5 288 Studies in Epidemiology (MOOSE) group. *JAMA*. 2000 Apr 19;283(15):2008–12.
- 7 289 26. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting
8 290 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
9 291 *Systematic Reviews*. 2015 Jan 1;4(1):1.
- 11 292 27. Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for
12 293 ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in
13 294 patients with a positive clinical history screening test for ankylosing spondylitis. *Br J Rheumatol*.
14 295 1985 Aug;24(3):242–9.
- 17 296 28. Chou CT, Tsai YF, Liu J, Wei JC, Liao TS, Chen ML, et al. The detection of the HLA-B27 antigen by
18 297 immunomagnetic separation and enzyme-linked immunosorbent assay-comparison with a flow
19 298 cytometric procedure. *J Immunol Methods*. 2001 Sep 1;255(1–2):15–22.
- 21 299 29. Monneret G, Seffert O, Debard AL, Gutowski MC, Couprie N, Larbre JP, et al. [Standardization
22 300 and automation of HLA B27 typing by flow cytometry: validation and comparison with
23 301 microlymphocytotoxicity]. *Ann Biol Clin (Paris)*. 2000 Aug;58(4):461–6.
- 26 302 30. World Bank Country and Lending Groups – World Bank Data Help Desk [Internet]. [cited 2020
27 303 May 24]. Available from: [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
28 304 [world-bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 30 305 31. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a
31 306 tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016 Oct
32 307 12;355:i4919.
- 34 308 32. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence
35 309 studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol*.
36 310 2012 Sep;65(9):934–9.
- 39 311 33. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials*. 2015
40 312 Nov;45(Pt A):139–45.
- 42 313 34. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of
43 314 controlled trials with binary endpoints. *Stat Med*. 2006 Oct 30;25(20):3443–57.
- 45 315 35. Miller JJ. The Inverse of the Freeman – Tukey Double Arcsine Transformation. *The American*
46 316 *Statistician*. 1978 Nov 1;32(4):138–138.
- 48 317 36. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in
49 318 meta-analysis: Q statistic or I2 index? *Psychol Methods*. 2006 Jun;11(2):193–206.
- 51 319 37. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
52 320 graphical test. *BMJ*. 1997 Sep 13;315(7109):629–34.
- 55 321 38. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)*. 2012;22(3):276–
56 322 82.
- 58 323
59
60

1
2
3 324 **Authors' contributions**
4
5

6 325 AH, SH and EA had the original idea. EA, AM, AH and JJB designed and conceived the protocol. AM, EA,
7
8 326 and AH drafted the manuscript. JJB, SH, and AC critically revised the manuscript for methodology and
9
10 327 intellectual content. EA and AH are the guarantors of the review. All authors approved the final version
11
12 328 of this manuscript.
13
14

15 329 **Funding**
16
17

18 330 The authors have not declared a specific grant for this research from any funding agency in the public,
19
20 331 commercial or not-for-profit sectors.
21
22

23 332 **Competing interests**
24
25

26 333 None declared.
27
28

29 334 **Patient consent for publication**
30
31

32 335 Not required.
33
34

35 336 **ORCID iDs**
36
37

38 337 Edem Allado (<http://orcid.org/0000-0002-1760-6979>)
39
40

41 338 Jean Joel Bigna (<http://orcid.org/0000-0001-8018-6279>)
42
43

44 339 Sabrina Hamroun (<http://orcid.org/0000-0003-2721-1249>)
45
46

47 340 Aghilès Hamroun (<http://orcid.org/0000-0003-4988-206X>)
48
49

50 341 Bruno Chenual (<https://orcid.org/0000-0001-6619-6577>)
51
52
53
54
55
56
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page No
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	NA
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	13
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
Support:			
Sources	5a	Indicate sources of financial or other support for the review	13
Sponsor	5b	Provide name for the review funder and/or sponsor	NA
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	NA
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5-6
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5-6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	7-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	7, suppl. tab 2

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	8
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	6
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	8-9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8-9
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	8-9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8-9

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

Global prevalence of spondyloarthritis in low-and-middle income countries: a systematic review and meta-analysis protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041180.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Aug-2020
Complete List of Authors:	ALLADO, Edem; Nancy Regional University Hospital Center, University Center of Sports Medicine and Adapted Physical Activity ; Lorraine European University Centre, EA 3450 DevAH, Development, Adaptation and Disadvantage. Cardiorespiratory regulations and motor control, MOUSSU, Anthony; Nancy Regional University Hospital Center, University Center of Sports Medicine and Adapted Physical Activity Bigna, Jean Joel; Centre Pasteur of Cameroon, Department of Epidemiology and Public Health HAMROUN, Sabrina; Paris University CAMIER, Aurore; INSERM, UMR1153 Center for Research in Epidemiology and Statistics (CRESS), Research Team on Early Life Origins of Health (EAROH) CHENUÉL, Bruno; Nancy Regional University Hospital Center, 1. University Center of Sports Medicine and Adapted Physical Activity ; Lorraine European University Centre, EA 3450 DevAH, Development, Adaptation and Disadvantage. Cardiorespiratory regulations and motor control, HAMROUN, Aghiles ; Paris-Saclay University, Centre for Research in Epidemiology and Population Health; Lille University Hospital Center, Nephrology Dialysis and Kidney Transplantation Department
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Rheumatology
Keywords:	RHEUMATOLOGY, EPIDEMIOLOGY, IMMUNOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Global prevalence of spondyloarthritis in low-and-middle income countries: a systematic review**
4
5 2 **and meta-analysis protocol.**
6
7

8 3 Edem Allado^{1,2,3}, Anthony Moussu¹, Jean Joel Bigna⁴, Sabrina Hamroun⁵, Aurore Camier⁶, Bruno
9 4 Chenuel^{1,2}, Aghilès Hamroun^{7,8}
10
11

12
13 5 **Author affiliations**
14

- 15 6 1. University Center of Sports Medicine and Adapted Physical Activity - University Hospital of
16 7 Nancy, F-54000, Nancy, France.
17
18 8 2. EA 3450 DevAH, Development, Adaptation and Disadvantage. Cardiorespiratory regulations
19 9 and motor control, University of Lorraine, F-54505, France
20
21 10 3. Department rheumatology - University Hospital of Nancy, F-54000, Nancy, France
22
23 11 4. Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé,
24 12 Cameroon
25
26 13 5. Université de Paris, F-75006, Paris, France
27
28 14 6. INSERM, UMR1153 Center for Research in Epidemiology and Statistics (CRESS), Research
29 15 Team on Early Life Origins of Health (EAROH), 75004 Paris, France
30
31 16 7. Centre for Research in Epidemiology and Population Health, Paris-Saclay University, UMRS
32 17 1018, Villejuif, France
33
34 18 8. University of Lille, Regional University Hospital Centre of Lille, Nephrology Dialysis and
35 19 Kidney Transplantation Department, F-59000 Lille, France
36
37
38
39
40
41
42
43
44

45
46 20 **Corresponding author:**
47

48 21 Edem ALLADO, MD, MSc
49

50 22 University Center of Sports Medicine and Adapted Physical Activity - University Hospital of Nancy, F-
51 23 54000, Nancy, France.
52

53 24 Mail : e.allado@chru-nancy.fr
54
55
56
57
58
59
60

25 **Abstract**

26 **Introduction:** In the past decade, the definition of spondyloarthritis (SpA) has undergone major
27 modifications in respect of new diagnostic tools and classifications. With the advent of biotherapies,
28 treatment possibilities in patients with SpA have substantially improved in the last few years. There is
29 great interest in obtaining accurate data on the disease prevalence, especially in regions where data
30 remains scarce such as low-and-middle income countries (LMICs), in order to measure and understand
31 the needs of their health care systems. Therefore, through a global systematic review and meta-analysis,
32 the current study aims to investigate the prevalence of SpA and Human Leukocyte Antigen B27
33 (HLAB27), and its association with the risk of SpA in the LMIC population.

34 **Methods and analysis:** We will include cohort, case-control and cross-sectional studies performed
35 among adults (> 15 years) living in LMICs. EMBASE, Medline, Global Index Medicus, and Web of
36 Knowledge will be searched for relevant records published until 30 April 2020, without any language
37 restriction. The review will be reported according to the Meta-analysis Of Observational Studies in
38 Epidemiology (MOOSE) guidelines. After screening of titles and abstracts, study selection, data
39 extraction and risk of bias assessment by two independent reviewers, we shall assess the studies
40 individually for clinical and statistical heterogeneity. Random-effect meta-analysis will be used to pool
41 studies judged to be clinically homogenous. The Egger's test and visual inspection of funnel plots will
42 be used to assess publication bias. Results will be presented by World Health Organization (WHO) sub-
43 regions.

44 **Ethics and dissemination:** Since primary data is not collected in this study, ethical approval is not
45 required. This review is expected to provide relevant data on the epidemiology of SpA, HLAB27 and
46 their association in the global population of LMICs. The final report will be published in a peer-reviewed
47 journal.

48 **Prospero registration number** CRD42020163898

49 **Strengths and limitations of this study**

- 1
2
3 50 - This will be the first systematic review summarizing data on the global burden of SpA in
4
5 51 LMICs, and its association with HLAB27.
6
7 52 - Rigorous methods and robust statistical analyses will be used to minimize bias and provide
8
9 53 accurate data.
10
11 54 - No language restriction will be applied, hence, allowing a maximum number of studies to be
12
13 55 included in this review.
14
15 56 - The limited number of studies on the topic may represent an important shortcoming, especially
16
17 57 for data regarding HLAB27 status.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

58 Introduction

59 Spondyloarthritis (SpA) is a common disease that affects 0.5 to 2% of the global population ¹⁻³. This
60 pathology is characterized by chronic inflammatory pain and debilitating stiffness, manifesting itself
61 most often in young adult men ⁴⁻⁶. It is associated with a negative impact on mental health, quality of
62 life and professional activity, generating significant costs ^{1,4,7,8}. The delay to diagnose this pathology is
63 often long, up to 10 years after the symptoms' onset, increasing the disease burden ^{9,10}. In our modern
64 era of new targeted therapies, it becomes essential to reduce this diagnostic delay, these treatments being
65 all the more effective as the disease is treated at an early-stage ^{11,12}.

66 The concept and definition of SpA have evolved significantly over the past thirty years ¹³⁻¹⁵, leading to
67 the current Assessment of Spondyloarthritis International Society (ASAS) classification criteria ^{16,17}.
68 The ASAS classification criteria also gives a central place to the detection of the Human Leukocyte
69 Antigen B27 (HLAB27) in the diagnostic and early referral process ¹⁸. SpA prevalence data seems to
70 highlight a strong association with the frequency of HLAB27 ^{19,20}, although this association is not
71 homogeneous depending on the areas of the globe: in fact, we note a frequent co-occurrence in Western
72 countries (around 90%), which would lower to 50% in Arab countries and become virtually absent in
73 sub-Saharan Africa where the prevalence of the HLAB27 antigen is very low (less than 1%) ²¹⁻²³.
74 Nevertheless, these global estimates are not generalizable to the population of low-and-middle income
75 countries (LMICs), where data is based on scattered studies, with a small number of patients, and in a
76 limited sample of countries (LMICs)²⁴. It is thus difficult to distinguish the exact cause of the data
77 heterogeneity, whether linked to demographic or genetic characteristics of the population, frequent
78 under-diagnosis due to a lack of available health care facilities and rheumatologists, or methodological
79 biases in data reporting ²⁴.

80 Accordingly, we propose this global systematic review and meta-analysis protocol to critically
81 synthesize current evidence on the burden of SpA in LMICs. This study will provide evidence-based
82 and useful data that may raise awareness in healthcare providers, researchers and policy makers for
83 improved detection and management of SpA in the global population of LMICs.

1
2
3 **84 Review question**
4
5

6 **85** What is the epidemiology of spondyloarthritis (and its axial form) in low-and-middle-income countries?
7

8
9 **86 Objectives**
10

11 **87** This systematic review and meta-analysis aims:
12

13
14 **88** 1. To determine the prevalence of axial spondyloarthritis in the global population (asymptomatic
15
16 **89** or referring for inflammatory back pain) in LMICs
17

18
19 **90** Other objectives:
20

21
22 **91** 2. To determine the prevalence of HLAB27 in the global population (asymptomatic, symptomatic
23
24 **92** and diagnosed spondyloarthritis) in LMICs
25

26 **93** 3. To determine the association between HLAB27 and the risk of spondyloarthritis in LMICs
27
28

29 **94 Methods and analysis**
30

31 **95** This systematic review and meta-analysis will be reported in conformity with the Meta-analysis Of
32
33 **96** Observational Studies in Epidemiology (MOOSE) guidelines ²⁵. The Preferred Reporting Items for
34
35 **97** Systematic Review and Meta-Analysis Protocol (PRISMA-P) was used to report this protocol ²⁶. The
36
37 **98** PRISMA-P checklist is attached as online **supplementary file 1**.
39

40
41 **99 Criteria for considering studies for the review**
42

43 **100** Spondylarthritis (SpA) will be diagnosed on the basis of clinical and imaging features, in accordance
44
45 **101** with ‘Assessment of SpondyloArthritis international Society’ (ASAS), ‘European Spondyloarthropathy
46
47 **102** Study Group’ (ESSG), New York, Rome or Amor criterion ^{13,14,18,27}. The presence of sacroiliitis will be
48
49 **103** assessed by MRI, CT-scan or X-ray, according to the modified New York criteria. HLAB27 detection
50
51 **104** will be assessed by ELISA, flow cytometry assay, genetic sequence-based, or micro-lymphocytotoxicity
52
53 **105** methods ^{28,29}. Studies where a different definition of SpA would have been used will be retrieved as well
54
55 **106** and a subgroup analysis will be conducted to assess the effect of the definition on the overall summary
56
57 **107** effect.
58
59
60

1
2
3 108 Only participants from LMICs will be included as classified by the World Bank³⁰. For the 2020
4
5 109 fiscal year, low-income economies are defined as those with a gross national income (GNI) per
6
7 110 capita, calculated using the World Bank Atlas method, of \$1025 or less in 2018; lower-middle-
8
9 111 income economies are those with a GNI per capita between \$1026 and \$3995; and upper-
10
11 112 middle-income economies are those with a GNI per capita between \$3996 and \$12,375.

12
13
14
15 113 **Specific criteria for estimating the prevalence of spondyloarthritis and HLAB27 in the global**
16
17 114 **population of LMICs**

- 18
19
20 115 1. Population: we will include adults (> 15 years), whether they are asymptomatic, symptomatic
21
22 116 (i.e. inflammatory back pain) or have a diagnosed spondyloarthritis.
23
24 117 2. Outcomes: we will consider studies reporting the prevalence of spondyloarthritis and/or
25
26 118 HLAB27, or studies having enough data to compute these estimates; which are number of SpA
27
28 119 or HLAB27 cases and total sample size.
29
30 120 3. Study design: we will consider cross-sectional and cohort studies.
31
32

33 121 **Specific criteria for investigating the association between HLAB27 and risk of SpA**

- 34
35
36 122 1. Population: we will consider adults (> 15 years) with or without any specific medical condition
37
38 123 or disease.
39
40 124 2. The exposure will be defined as being HLAB27 positive.
41
42 125 3. The comparator will be defined as a confirmed absence of HLAB27 detection. Patients with
43
44 126 'Confirmed absence of HLAB27 detection' are HLAB27 negative using the same method of
45
46 127 diagnostic as those HLAB27 positive.
47
48 128 4. The outcome will be the presence of SpA, including its axial form, according to prespecified
49
50 129 diagnostic criteria.
51
52 130 5. We will consider cross-sectional, case-control and cohort studies. We will consider studies in
53
54 131 which both patients HLAB27 positive (exposed group) and HLAB27 negative (non-exposed
55
56 132 group) are included; and where the proportion of patients with SpA was reported in both groups.
57
58
59 133

134 **Search strategy for identifying relevant studies**

135 The search strategy will be conducted as follows.

136 **Bibliographic database searches**

137 Relevant records will be identified by searching EMBASE, PubMed, Global Index Medicus and Web
138 of knowledge from inception to 30 April 2020. Text words and medical subject heading terms related
139 to SpA and HLAB27 will be used including: ‘ankylosing spondylitis’, ‘sacroiliitis’, ‘Bechterew
140 Disease’, ‘Spondyloarthritis Ankylopoietica’, ‘Marie Struempell Disease’, ‘spine disease’, and ‘HLA-
141 B27’. The name of the LMICs (as defined by the World Bank Classification)³⁰ in the language relevant
142 to each country will also be applied. **Supplementary file 2** shows the full search strategy for EMBASE
143 that will be adapted to fit with other databases. No language restriction will be applied. For articles
144 published in a language other than English and French, an experienced translator in the concerned
145 language will be contacted for translation.

146 **Searching for other sources**

147 We will scan the references of all relevant articles for additional relevant data sources missed during our
148 search, and their full-texts will be retrieved. References of pertinent reviews will also be scanned.

149 **Selection of studies for inclusion in the review**

150 All references identified after implementation of the search strategy will be imported into Zotero
151 software. All records obtained from various databases will be combined in a single Zotero library, and
152 duplicates will be removed. Two reviewers (AH and EA) will independently evaluate the studies
153 obtained from the searches, using an assessment form to ensure that selection criteria are reliably
154 applied. These reviewers will screen the titles and abstracts of papers obtained, after which the full texts
155 of potentially eligible papers will be retrieved by one reviewer (AH). The two reviewers will
156 independently review the full text of each potentially eligible study, compare their results and resolve
157 any discrepancy by discussion. For duplicates, studies published in more than one report, the one

1
2
3 158 reporting the largest sample size will be considered. Studies with inaccessible full text either online or
4
5 159 from the corresponding author will be excluded.
6
7

8 160 **Assessment of methodological quality and reporting of data**

9

10 161 Methodological quality and risk of bias of included studies will be independently assessed by two
11
12 162 reviewers using the Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) tool for
13
14 163 studies investigating the association between HLAB27 and SpA.³¹ For studies investigating prevalence
15
16 164 estimates, we will use the risk of bias tool developed by Hoy and colleagues.³²
17
18
19

20 165 **Data extraction and management**

21

22 166 A data extraction form will be used to collect information on the surname of the first author, year of
23
24 167 publication, country where the study was conducted, study design, study area (rural, urban), sampling
25
26 168 method, timing of data collection, population setting (general population, hospitalized patients), type of
27
28 169 population (healthy asymptomatic, inflammatory back pain, SpA diagnosed patients), method of SpA
29
30 170 diagnostic, method of HLAB27 detection, mean or median age, proportion of males, specific
31
32 171 characteristics of the study population, sample size, number of SpA cases, and number of HLAB27
33
34 172 positive cases. For multinational studies, data will be reported for the individual countries. Where it will
35
36 173 be impossible to disaggregate data for such studies by country, available data will be presented as a
37
38 174 single study, and each individual country which participated in the study will be reported. We will
39
40 175 exclude studies in which relevant data are impossible to extract even after contacting the corresponding
41
42 176 author.
43
44
45

46 177 **Data synthesis and analysis**

47

48
49 178 In order to measure the association between HLAB27 positivity and risk of SpA, a meta-analysis using
50
51 179 the random-effects method of DerSimonian and Laird will be performed to pool weighted Odds Ratios
52
53 180 (ORs) of risk estimates³³. ORs will be reported with their 95% confidence intervals (95% CIs), and 95%
54
55 181 prediction intervals³⁴.
56
57
58
59
60

1
2
3 182 For prevalence synthesis, unadjusted prevalences with their respective standard errors will be
4
5 183 recalculated based on the information of crude numerators and denominators provided by individual
6
7 184 studies. The variance of the study-specific prevalence will be stabilized with the Freeman-Tukey double
8
9 185 arc-sine transformation, before pooling the data using a random-effects meta-analysis model³⁵. All
10
11 186 pooled estimate will be reported with 95% CI and 95% prediction interval. Heterogeneity will be
12
13 187 assessed using the χ^2 test on Cochran's Q statistic, and quantified by calculating I².³⁶ Values of 25%,
14
15 188 50% and 75% for I², will respectively represent low, medium and high heterogeneity. We will assess
16
17 189 the presence of publication bias using funnel plots inspection (if ≥ 10 studies) and the Egger's test (if \geq
18
19 190 3 studies)³⁷. When there will be enough data, meta-regression and subgroup analyses will be performed
20
21 191 to investigate possible sources of heterogeneity using the aforementioned variables and the study
22
23 192 methodological quality. We plan to do subgroup analysis according to: SpA form (all forms confounded
24
25 193 or axial form only), population type, population settings, WHO subregions, and the definition used to
26
27 194 diagnose SpA. In case of substantial clinical heterogeneity, a narrative summary of findings will be
28
29 195 done. The inter-rater agreement for study inclusion between investigators will be assessed using Cohen's
30
31 196 κ coefficient³⁸. Data analyses will be done using the 'meta' package of the statistical software R v.3.6.2.

35 197 **Presentation and reporting of results**

36
37
38 198 The study selection process will be summarized using a flow diagram. Quantitative data will be
39
40 199 presented in tables of individual studies, and in summary tables, or forest plots where appropriate. The
41
42 200 quality score of bias for each eligible study will be reported accordingly.

45 201 **Patient and public involvement**

46
47
48 202 Patients and the public were not involved in the design or planning of the study.

50 203 **Potential amendments**

51
52
53 204 We do not plan to modify the protocol to avoid reporting bias. However, if necessary, any amendment
54
55 205 in the review process will be reported for transparency.

58 206 **Ethics and dissemination**

207 Since primary data is not collected in this study, ethical approval is not required. This review is expected
208 to provide accurate data on SpA and HLAB27 prevalences, as well as an estimation of their association
209 in LMICs. The final report will be published in a peer-reviewed journal.

210 **Review status and expected deadlines**

211 Bibliographic database searches (April-May 2020), selection of included studies (June-August 2020),
212 data extraction and management (September-December 2020), data synthesis and analysis (January-
213 February 2021), manuscript submission (April 2021).

214 **References**

- 215 1. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. *J Rheumatol Suppl.* 2006
216 Sep;78:4–11.
- 217 2. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence
218 of ankylosing spondylitis. *Rheumatology (Oxford).* 2014 Apr 1;53(4):650–7.
- 219 3. Dougados M, Baeten D. Spondyloarthritis. *Lancet.* 2011 Jun 18;377(9783):2127–37.
- 220 4. Poddubnyy D, Rudwaleit M. Early spondyloarthritis. *Rheum Dis Clin North Am.* 2012
221 May;38(2):387–403.
- 222 5. Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. *Nat Rev Dis Primers.* 2015
223 09;1:15013.
- 224 6. Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. *Best
225 Practice & Research Clinical Rheumatology.* 2006 Jun 1;20(3):401–17.
- 226 7. Martindale J, Shukla R, Goodacre J. The impact of ankylosing spondylitis/axial spondyloarthritis
227 on work productivity. *Best Pract Res Clin Rheumatol.* 2015 Jun;29(3):512–23.
- 228 8. Zhao S, Thong D, Miller N, Duffield SJ, Hughes DM, Chadwick L, et al. The prevalence of
229 depression in axial spondyloarthritis and its association with disease activity: a systematic
230 review and meta-analysis. *Arthritis Res Ther.* 2018 11;20(1):140.
- 231 9. Zhao S, Pittam B, Harrison NL, Nursiah K, Goodson NJ, Hughes DM. Systematic review and
232 meta-analysis of diagnostic delay in axial spondyloarthritis. 2020 Apr 8 [cited 2020 May 24];
233 Available from: <http://livrepository.liverpool.ac.uk/3081611>
- 234 10. Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, Economic, and Humanistic Burden
235 Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review. *Rheumatol
236 Ther.* 2020 Mar;7(1):65–87.
- 237 11. Sykes MP, Doll H, Sengupta R, Gaffney K. Delay to diagnosis in axial spondyloarthritis: are we
238 improving in the UK? *Rheumatology (Oxford).* 2015 Dec;54(12):2283–4.

- 1
2
3 239 12. Seo MR, Baek HL, Yoon HH, Ryu HJ, Choi H-J, Baek HJ, et al. Delayed diagnosis is linked to worse
4 240 outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. *Clin*
5 241 *Rheumatol*. 2015 Aug;34(8):1397–405.
- 7 242 13. Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. *Rev*
8 243 *Rhum Mal Osteoartic*. 1990 Feb;57(2):85–9.
- 10 244 14. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European
11 245 Spondylarthropathy Study Group preliminary criteria for the classification of
12 246 spondylarthropathy. *Arthritis Rheum*. 1991 Oct;34(10):1218–27.
- 15 247 15. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing
16 248 spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum*. 1984
17 249 Apr;27(4):361–8.
- 19 250 16. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development
20 251 of Assessment of SpondyloArthritis international Society classification criteria for axial
21 252 spondyloarthritis (part I): classification of paper patients by expert opinion including
22 253 uncertainty appraisal. *Ann Rheum Dis*. 2009 Jun;68(6):770–6.
- 25 254 17. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development
26 255 of Assessment of SpondyloArthritis international Society classification criteria for axial
27 256 spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*. 2009 Jun;68(6):777–
28 257 83.
- 30 258 18. Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. *Nat Rev*
31 259 *Rheumatol*. 2012 Apr 10;8(5):262–8.
- 33 260 19. Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA-B27 in the US:
34 261 data from the US National Health and Nutrition Examination Survey, 2009. *Arthritis Rheum*.
35 262 2012 May;64(5):1407–11.
- 37 263 20. Khan MA. HLA-B27 and its subtypes in world populations. *Curr Opin Rheumatol*. 1995
38 264 Jul;7(4):263–9.
- 41 265 21. Mustafa KN, Hammoudeh M, Khan MA. HLA-B27 Prevalence in Arab Populations and Among
42 266 Patients with Ankylosing Spondylitis. *J Rheumatol*. 2012 Aug;39(8):1675–7.
- 44 267 22. Ziade NR. HLA B27 antigen in Middle Eastern and Arab countries: systematic review of the
45 268 strength of association with axial spondyloarthritis and methodological gaps. *BMC*
46 269 *Musculoskelet Disord*. 2017 Jun 29;18(1):280.
- 48 270 23. Mathieu A, Paladini F, Vacca A, Cauli A, Fiorillo MT, Sorrentino R. The interplay between the
49 271 geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune
50 272 diseases: a unifying hypothesis. *Autoimmun Rev*. 2009 Mar;8(5):420–5.
- 53 273 24. Stolwijk C, Onna M van, Boonen A, Tubergen A van. Global Prevalence of Spondyloarthritis: A
54 274 Systematic Review and Meta-Regression Analysis. *Arthritis Care & Research*. 2016;68(9):1320–
55 275 31.
- 57 276 25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of
58 277 observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational
59 278 Studies in Epidemiology (MOOSE) group. *JAMA*. 2000 Apr 19;283(15):2008–12.

- 1
2
3 279 26. Moher D, Shamseer L, Clarke M, Gherzi D, Liberati A, Petticrew M, et al. Preferred reporting
4 280 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
5 281 Systematic Reviews. 2015 Jan 1;4(1):1.
6
7 282 27. Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for
8 283 ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in
9 284 patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol.
10 285 1985 Aug;24(3):242–9.
11
12 286 28. Chou CT, Tsai YF, Liu J, Wei JC, Liao TS, Chen ML, et al. The detection of the HLA-B27 antigen by
13 287 immunomagnetic separation and enzyme-linked immunosorbent assay-comparison with a flow
14 288 cytometric procedure. J Immunol Methods. 2001 Sep 1;255(1–2):15–22.
15
16 289 29. Monneret G, Seffert O, Debard AL, Gutowski MC, Couprie N, Larbre JP, et al. [Standardization
17 290 and automation of HLA B27 typing by flow cytometry: validation and comparison with
18 291 microlymphocytotoxicity]. Ann Biol Clin (Paris). 2000 Aug;58(4):461–6.
19
20 292 30. World Bank Country and Lending Groups – World Bank Data Help Desk [Internet]. [cited 2020
21 293 May 24]. Available from: [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
22 294 [world-bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
23
24 295 31. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a
25 296 tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct
26 297 12;355:i4919.
27
28 298 32. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence
29 299 studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol.
30 300 2012 Sep;65(9):934–9.
31
32 301 33. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015
33 302 Nov;45(Pt A):139–45.
34
35 303 34. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of
36 304 controlled trials with binary endpoints. Stat Med. 2006 Oct 30;25(20):3443–57.
37
38 305 35. Miller JJ. The Inverse of the Freeman – Tukey Double Arcsine Transformation. The American
39 306 Statistician. 1978 Nov 1;32(4):138–138.
40
41 307 36. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in
42 308 meta-analysis: Q statistic or I2 index? Psychol Methods. 2006 Jun;11(2):193–206.
43
44 309 37. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
45 310 graphical test. BMJ. 1997 Sep 13;315(7109):629–34.
46
47 311 38. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–
48 312 82.
49
50 313
51
52
53
54
55
56
57 314
58
59
60 315

1
2
3 316 **Authors' contributions**
4
5

6 317 AH, SH and EA had the original idea. EA, AM, AH and JJB designed and conceived the
7
8 318 protocol. AM, EA, and AH drafted the manuscript. BC, JJB, SH, and AC critically revised the
9
10 319 manuscript for methodology and intellectual content. EA and AH are the guarantors of the
11
12
13 320 review. All authors approved the final version of this manuscript.
14
15

16 321 **Acknowledgements**
17

18 322 Thank you to Doctor Paul Chamley for his valuable proof-reading.
19
20

21 323 **Funding**
22
23

24 324 The authors have not declared a specific grant for this research from any funding agency in the
25
26 325 public, commercial or not-for-profit sectors.
27
28

29 326 **Competing interests**
30

31
32 327 None declared.
33
34

35 328 **Patient consent for publication**
36

37
38 329 Not required.
39
40

41 330 **ORCID iDs**
42
43

44 331 Edem Allado (<http://orcid.org/0000-0002-1760-6979>)
45
46

47 332 Jean Joel Bigna (<http://orcid.org/0000-0001-8018-6279>)
48
49

50 333 Sabrina Hamroun (<http://orcid.org/0000-0003-2721-1249>)
51
52

53 334 Aghilès Hamroun (<http://orcid.org/0000-0003-4988-206X>)
54
55

56 335 Bruno Chenuel (<https://orcid.org/0000-0001-6619-6577>)
57
58
59
60

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page No
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	NA
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	13
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
Support:			
Sources	5a	Indicate sources of financial or other support for the review	13
Sponsor	5b	Provide name for the review funder and/or sponsor	NA
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	NA
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5-6
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5-6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	7-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	7, suppl. tab 2

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	8
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	6
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	8-9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8-9
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	8-9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8-9

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Additional file 2. Generic Search Strategy.**Targeted databases:** PubMed, EMBASE, Global Index Medicus, and Web of knowledge**Period:** from inception to 30 September 2019

Search	Search terms
#1	"ankylosing spondylitis" OR "Spondyloarthritis Ankylopoietica" OR "Ankylosing Spondylarthritis" OR "Spondylarthritis Ankylopoietica" OR "Bechterew Disease" OR "Bchterews Disease" OR "Marie Struempell Disease" OR "Rheumatoid Spondylitis" OR "Ankylosing Spondyloarthritis" OR 'spine disease' OR 'spondylarthropathy' OR spondylarthropathies OR spondylarthritis OR sacroiliitis OR "HLA-B27" OR Ankylosis
#2	Afghanistan OR Albania OR Algeria OR "American Samoa" OR Angola OR Argentina OR Armenia OR Azerbaijan OR Bangladesh OR Belarus OR Belize OR Benin OR Bhutan OR Bolivia OR "Bosnia and Herzegovina" OR Botswana OR Brazil OR Bulgaria OR "Burkina Faso" OR Burundi OR Cabo Verde OR Cambodia OR Cameroon OR "Central African Republic" OR Chad OR China OR Colombia OR Comoros OR "Democratic Republic of Congo" OR Congo OR "Republic of Congo" OR "Costa Rica" OR "Ivory Coast" OR "Cote Ivoire" OR Cuba OR Djibouti OR Dominica OR "Dominican Republic" OR Ecuador OR Egypt OR "El Salvador" OR Salvador OR "Equatorial Guinea" OR Guinea OR Eritrea OR Ethiopia OR Fiji OR Gabon OR Gambia OR Georgia OR Ghana OR Grenada OR Guatemala OR Guinea OR "Guinea-Bissau" OR Guyana OR Haiti OR Honduras OR India OR Indonesia OR Iran OR Iraq OR Jamaica OR Jordan OR Kazakhstan OR Kenya OR Kiribati OR Korea OR Kosovo OR Kyrgyz OR "Lao PDR" OR Lao OR Lebanon OR Lesotho OR Liberia OR Libya OR Macedonia OR Madagascar OR Malawi OR Malaysia OR Maldives OR Mali OR "Marshall Islands" OR Mauritania OR Mauritius OR Mexico OR Micronesia OR Moldova OR Mongolia OR Montenegro OR Morocco OR Mozambique OR Myanmar OR Namibia OR Nepal OR Nicaragua OR Niger OR Nigeria OR Pakistan OR Palau OR Panama OR Papua New Guinea OR Paraguay OR Peru OR Philippines OR Romania OR "Russian Federation" OR Russia OR Rwanda OR Samoa OR "Sao Tomé and Príncipe" OR Senegal OR Serbia OR "Sierra Leone" OR "Solomon Islands" OR Somalia OR "South Africa" OR "South Sudan" OR "Sri Lanka" OR "St Lucia" OR "Vincent and the Grenadines" OR Sudan OR Suriname OR Swaziland OR "Syrian Arab Republic" OR Syria OR Tajikistan OR Tanzania OR Thailand OR "Timor-Leste" OR Timor OR Togo OR Tonga OR Tunisia OR Turkey OR Turkmenistan OR Tuvalu OR Uganda OR Ukraine OR Uzbekistan OR Vanuatu OR Venezuela OR Vietnam OR "West Bank and Gaza" OR Gaza OR Yemen OR Zambia OR Zimbabwe
#3	#1 AND #2

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page No
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	NA
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	13
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
Support:			
Sources	5a	Indicate sources of financial or other support for the review	13
Sponsor	5b	Provide name for the review funder and/or sponsor	NA
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	NA
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5-6
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5-6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	7-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	7, suppl. tab 2

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	8
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	6
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	8-9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8-9
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	8-9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8-9

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.